Mount Sinai opens research center focused on biomedical blockchain

New York’s Icahn School of Medicine at Mount Sinai, along with the Institute for Next Generation Healthcare, announced the opening of the Center of Biomedical Blockchain Research on Tuesday, July 24.

“There is a lot of excitement around the possibilities for blockchain technology in healthcare,” said Joel Dudley, PhD, executive vice president of precision health at Mount Sinai. “However, we still have lots of hard work ahead to identify the most salient features of blockchain technologies to solve real-word healthcare problems.”

The center will examine applications for blockchain, “a distributed, decentralized secure database system originally developed for Bitcoin, to solve problems in health care and medical science,” according to a Mount Sinai release. Researchers will aim to conduct evaluations of blockchain-enabled solutions, provide partnerships with companies working in the technology and build and test systems within the Mount Sinai Health System.

“At Mount Sinai, we bring to the table deep expertise in biomedical data, machine learning, and data governance. This experience will allow us to address many of the most promising uses for blockchain in biomedicine with the goal of improving healthcare delivery and reducing costs,” said Noah Zimmerman, PhD, assistant professor of genetics and genomic sciences.

Companies are already investigating blockchain as a way of encouraging drug development, expanding access to healthcare and improving quality control.

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup